A 48-year-old woman with metastatic HER2-positive breast cancer has completed 6 cycles of trastuzumab plus docetaxel. Restaging imaging shows stable disease. She tolerates the regimen well with no cardiac dysfunction (LVEF 55%). What is the most appropriate next step in management?

See the options, answer & explanation

Sign in free to reveal the answer choices, the correct answer, the detailed explanation, and AI-powered insights for this question.